Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes

Endocrinology

Volumn 153, Issue 3, 2012, Pages 1039-1048

  Cryer, Philip E ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN; SMALL INTERFERING RNA; SOMATOSTATIN;

GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; SOMATOSTATIN RELEASE;

ANIMALS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-SECRETING CELLS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN; MICE; MODELS, BIOLOGICAL; RATS; SOMATOSTATIN;

EID: 84857401843     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1499     Document Type: Short Survey

References (111)

1. Cherrington AD 2001 Control of glucose production in vivo by insulin and glucagon. In: Jefferson LS, Cherrington AD, eds. Handbook of physiology. Section 7: the endocrine system. Vol II: the endocrine pancreas and regulation of metabolism. New York: Oxford University Press; 759-785
2. Gustavson SM, Chu CA, Nishizawa M, Farmer B, Neal D, Yang Y, Vaughan S, Donahue EP, Flakoll P, Cherrington AD 2003 Glucagon's actions are modified by the combination of epinephrine and gluconeogenic precursor infusion. Am J Physiol Endocrinol Metab 285:E534-E544 (Pubitemid 37010831)
3. Ramnanan CJ, Edgerton DS, Kraft G, Cherrington AD 2011 Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab 13(Suppl 1):118-125
4. McGarry JD, Foster DW 1980 Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem 49: 395-420
5. Xiao C, Pavlic M, Szeto L, Patterson BW, Lewis GF 2011 Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans. Diabetes 60:383-390
6. Ranganath L, Schaper F, Gama R, Morgan L 2001 Does glucagon have a lipolytic effect? Clin Endocrinol (Oxf) 54:125-126 (Pubitemid 32158715)
7. Bertin E, Arner P, Bolinder J, Hagström-Toft E 2001 Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J Clin Endocrinol Metab 86:1229-1234 (Pubitemid 32323009)
8. Gravholt CH, Møller N, Jensen MD, Christiansen JS, Schmitz O 2001 Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. J Clin Endocrinol Metab 86:2085-2089 (Pubitemid 32472924)
9. Garber AJ, Cryer PE, Santiago JV, Haymond MW, Pagliara AS, Kipnis DM 1976 The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. J Clin Invest 58:7-15
10. Gerich J, Davis J, Lorenzi M, Rizza R, Bohannon N, Karam J, Lewis S, Kaplan R, Schultz T, Cryer P 1979 Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. Am J Physiol 236:E380-E385 (Pubitemid 9174549)
11. Rizza RA, Cryer PE, Gerich JE 1979 Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined α- and β-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest 64:62-71 (Pubitemid 9216520)
12. Cryer PE 2001 The prevention and correction of hypoglycemia. In: Jefferson LS, Cherrington AD, eds. Handbook of physiology. Section 7: the endocrine system. Vol II: the endocrine pancreas and regulation of metabolism. New York: Oxford University Press; 1057-1092
13. Dagogo-Jack SE, Craft S, Cryer PE 1993 Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus: recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 91:819-828 (Pubitemid 23095255)
14. Segel SA, Paramore DS, Cryer PE 2002 Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 51:724-733 (Pubitemid 34760182)
15. Cryer PE 2009 Hypoglycemia in diabetes: pathophysiology, prevalence and prevention. Alexandria, VA: American Diabetes Association; 45-95
16. Dunning BE, Gerich JE 2007 The role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 28:253-283 (Pubitemid 46984828)
17. Gerich JE, Lorenzi M, Bier DM, Schneider V, Tsalikian E, Karam JH, Forsham PH 1975 Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon.NEngl J Med 292:985-989
18. Gerich JE, Schneider VS, Lorenzi M, Tsalikian E, Karam JH, Bier DM, Forsham PH 1976 Role of glucagon in human diabetic ketoacidosis: studies using somatostatin. Clin Endocrinol (Oxf) 5(Suppl):299S-305S
19. Rizza RA 2010 Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes 59: 2697-2707
20. Shah P, Basu A, Basu R, Rizza R 1999 Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 277(2 Pt 1):E283-E290 (Pubitemid 29413834)
21. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA 2000 Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053-4059 (Pubitemid 32055352)
22. Unger RH, Orci L 2010 Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci USA 107:16009-16012
23. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH 2011 Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60:391-397
24. Ahrén B 2009 β- and α-cell dysfunction in subjects developing impaired glucose tolerance. Diabetes 58:726-731
25. Walker JN, Ramracheya R, Zhang Q, Johnson PRV, Braun M, Rorsman P 2011 Regulation of glucagon secretion by glucose: paracrine, intrinsic or both? Diabetes Obes Metab 13(Suppl 1): 95-105
26. Samols E, Tyler J Marks V 1972 Glucagon-insulin interrelationships. In: Lefebvre P, Unger RH, eds. Glucagon: molecular physiology, clinical and therapeutic implications. Elmsford, NY: Pergamon Press; 151-174
27. Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH 1984 Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 74:2296-2299 (Pubitemid 15197376)
28. Meier JJ, Kjems LL, Veldhuis JD, Lefèbvre P, Butler PC 2006 Post-prandial suppression of glucagon secretion depends on intact pulsatile insulin secretion. Diabetes 55:1051-1056
29. Gromada J, Franklin I, Wollheim CB 2007 Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28:84-116 (Pubitemid 46220851)
30. Braun M, Ramracheya R, Amisten S, Bengtsson M, Moritoh Y, Zhang Q, Johnson PR, Rorsman P 2009 Somatostatin release, electrical activity, membrane currents and exocytosis in human pancreatic δ-cells. Diabetologia 52:1566-1578
31. Taborsky Jr GJ, Ahrén B, Havel PJ 1998 Autonomic mediation of glucagon secretion during hypoglycemia. Diabetes 47:995-1005
32. Marty N, Dallaporta M, Thorens B 2007 Brain glucose sensing, counterregulation, and energy homeostasis. Physiology (Bethesda) 22:241-251
33. Holst JJ 2007 The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439 (Pubitemid 350041474)
34. Cabrera O, Jacques-Silva MC, Speier S, Yang SN, Köhler M, Fachado A, Vieira E, Zierath JR, Kibbey R, Berman DM, Kenyon NS, Ricordi C, Caicedo A, Berggren PO 2008 Glutamate is a positive autocrine signal for glucagon release. Cell Metab 7:545-554 (Pubitemid 351729201)
35. Biggers DW, Myers SR, Neal D, Stinson R, Cooper NB, Jaspan JB, Williams PE, Cherrington AD, Frizzell RT 1989 Role of brain in counterregulation of insulin-induced hypoglycemia in dogs. Diabetes 38:7-16 (Pubitemid 19021810)
36. Havel PJ, Ahren B 1997 Activation of autonomic nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women. Diabetes 46: 801-807 (Pubitemid 27188257)
37. Palmer JP, Henry DP, Benson JW, Johnson DG, Ensinck JW 1976 Glucagon response to hypoglycemia in sympathectomized man. J Clin Invest 57:522-525
38. Frier BM, Corrall RJ, Ratcliffe JG, Ashby JP, McClemont EJ 1981 Autonomic neural control mechanisms of substrate and hormonal responses to acute hypoglycaemia in man. Clin Endocrinol (Oxf) 14:425-433 (Pubitemid 12191727)
39. Diem P, Redmon JB, Abid M, Moran A, Sutherland DE, Halter JB, Robertson RP 1990 Glucagon, catecholamine and pancreatic polypeptide secretion in type I diabetic recipients of pancreas allografts. J Clin Invest 86:2008-2013
40. Sherck SM, Shiota M, Saccomando J, Cardin S, Allen EJ, Hastings JR, Neal DW, Williams PE, Cherrington AD 2001 Pancreatic response to mild non-insulin induced hypoglycemia does not involve extrinsic neural input. Diabetes 50:2487-2496 (Pubitemid 33642766)
41. Gerich JE, Charles MA, Grodsky GM 1974 Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas. J Clin Invest 54:833-841
42. Yue JTY, Burdett E, Coy DH, Efendic S, Vranic M 2009 Normalization of the glucagon response to hypoglycemia in STZ-diabetic rats via somatostatin type 2 receptor antagonism. Diabetes 58:A35 (Abstract)
43. Dufrane D, Maillart JF, Aouassar N, Goebbels RM, Guiot Y, Gianello P 2009 Native pancreatic α-cell adaptation in streptozotocin- induced diabetic primates: importance for pig islet xenotransplantation. Xenotransplantation 16:152-163
44. Zhou H, Zhang T, Harmon JS, Bryan J, Robertson RP 2007 Zinc, not insulin, regulates the rat α-cell response to hypoglycemia in vivo. Diabetes 56:1107-1112 (Pubitemid 46525066)
45. Stagner JI, Samols E 1992 The vascular order of islet cellular perfusion in the human pancreas. Diabetes 41:93-97
46. Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A 2006 The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA 103:2334-2339 (Pubitemid 43271670)
47. Cooperberg BA, Cryer PE 2010 Insulin reciprocally regulates glucagon secretion in humans. Diabetes 59:2936-2940
48. Bansal P, Wang Q 2008 Insulin as a physiological modulator of glucagon secretion. Am J Physiol Endocrinol Metab 295:E751-E761
49. Galassetti P, Davis SN 2000 Effects of insulin per se on neuroendocrine and metabolic counter-regulatory responses to hypoglycaemia. Clin Sci (Lond) 99:351-362
50. Brunicardi FC, Kleinman R, Moldovan S, Nguyen TH, Watt PC, Walsh J, Gingerich R 2001 Immunoneutralization of somatostatin, insulin and glucagon causes alterations in islet cell secretion in the isolated perfused human pancreas. Pancreas 23:302-308 (Pubitemid 32910980)
51. Franklin I, Gromada J, Gjinovci A, Theander S, Wollheim CB 2005 β-Cell secretory products activate α-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 54:1808-1815 (Pubitemid 40770771)
52. Diao J, Asghar Z, Chan CB, Wheeler MB 2005 Glucose-regulated glucagon secretion requires insulin receptor expression in pancreatic α-cells. J Biol Chem 280:33487-33496 (Pubitemid 41397148)
53. Xu E, Kumar M, Zhang Y, Ju W, Obata T, Zhang N, Liu S, Wendt A, Deng S, Ebina Y, Wheeler MB, Braun M, Wang Q 2006 Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metab 3:47-58
54. Kawamori D, Kurpad AJ, Hu J, Liew CW, Shih JL, Ford EL, Herrera PL, Polonsky KS, McGuinness OP, Kulkarni RN 2009 Insulin signaling in α-cells modulates glucagon secretion in vivo. Cell Metab 9:350-361
55. Banarer S, McGregor VP, Cryer PE 2002 Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes 51:958-965 (Pubitemid 34438337)
56. Raju B, Cryer PE 2005 Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes. Diabetes 54:757-764 (Pubitemid 40322079)
57. Gosmanov NR, Szoke E, Israelian Z, Smith T, Cryer PE, Gerich JE, Meyer C 2005 Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans. Diabetes Care 28: 1124-1131 (Pubitemid 40616623)
58. Israelian Z, Gosmanov NR, Szoke E, Schorr M, Bokhari S, Cryer PE, Gerich JE, Meyer C 2005 Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes. Diabetes Care 28:2691-2696 (Pubitemid 43951161)
59. Cooperberg BA, Cryer PE 2009 β-Cell-mediated signaling predominates over direct α-cell signaling in the regulation of glucagon secretion in humans. Diabetes Care 32:2275-2280
60. Towler DA, Havlin CE, Craft S, Cryer P 1993 Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 42:1791-1798 (Pubitemid 23346416)
61. Fukuda M, Tanaka A, Tahara Y, Ikegami H, Yamamoto Y, Kumahara Y, Shima K 1988 Correlation between minimal secretory capacity of pancreatic β-cells and stability of diabetic control. Diabetes 37:81-88 (Pubitemid 18036462)
62. Menge BA, Grüber L, Jørgensen SM, Deacon CF, Schmidt WE, Veldhuis JD, Holst JJ, Meier JJ 2011 Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes. Diabetes 60:2160-2168
63. Brown RJ, Sinaii N, Rother KI 2008 Too much glucagon, too little insulin. Diabetes Care 31:1403-1404
64. Pörksen S, Nielsen LB, Kaas A, Kocova M, Chiarelli F, Orskov C, Holst JJ, Ploug KB, Hougaard P, Hansen L, Mortensen HB; Hvidøre Study Group on Childhood Diabetes 2007 Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes. J Clin Endocrinol Metab 92:2910-2916
65. Abdul-Ghani M, DeFronzo RA 2007 Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretion. J Clin Endocrinol Metab 92:1778-1784 (Pubitemid 46997188)
66. Ramanathan RP, Arbeláez AM, Cryer PE 2011 Partial inhibition of insulin secretion results in glucose intolerance but not hyperglucagonemia. Diabetes 60:1324-1328
67. Lins PE, Efendić S 1976 Hyperglycemia induced by somatostatin in normal subjects. Horm Metab Res 8:497-498
68. Liljenquist JE, Mueller GL, Cherrington AD, Keller U, Chiasson J-L, Perry JM, Lacy WW, Rabinowitz D 1977 Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest 59:369-374 (Pubitemid 8055697)
69. Sherwin RS, Hendler R, DeFronzo R, Wahren J, Felic P 1977 Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin. Proc Natl Acad Sci USA 74:348-352 (Pubitemid 8025851)
70. Rosen SG, Clutter WE, Berk MA, Shah SD, Cryer PE 1984 Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man. J Clin Invest 73:405-411 (Pubitemid 14194620)
71. Breckenridge SM, Cooperberg BA, Arbelaez AM, Patterson BW, Cryer PE 2007 Glucagon, in concert with insulin, supports the postabsorptive plasma glucose concentration in humans. Diabetes 56:2442-2448 (Pubitemid 47523251)
72. Breckenridge SM, Raju B, Arbelaez AM, Patterson BW, Cooperberg BA, Cryer PE 2007 Basal insulin, glucagon, and growth hormone replacement. Am J Physiol Endocrinol Metab 293:E1303-E1310 (Pubitemid 350106598)
73. Cooperberg BA, Cryer PE 2010 Glucagon supports postabsorptive plasma glucose concentrations in humans with biologically optimal insulin levels. Diabetes 59:2941-2944
74. Brand CL, Jørgensen PN, Svendsen I, Holst JJ 1996 Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 45:1076-1083 (Pubitemid 26260161)
75. Lau YY, Ma P, Gibiansky L, Komorowski R, Wang J, Wang G, Yan H, Véniant MM, Kakkar T 2009 Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice. AAPS J 11:700-709
76. Kim RM, Chang J, Lins AR, Brady E, Candelore MR, Dallas-Yang Q, Ding V, Dragovic J, Iliff S, Jiang G, Mock S, Qureshi S, Saperstein R, Szalkowski D, Tamvakopoulos C, Tota L, Wright M, Yang X, Tata JR, Chapman K, Zhang BB, Parmee ER 2008 Discovery of potent, orally active benzimidazole glucagon receptor antagonists. Bioorg Med Chem Lett 18:3701-3705
77. Rivera N, Everett-Grueter CA, Edgerton DS, Rodewald T, Neal DW, Nishimura E, Larsen MO, Jacobsen LO, Kristensen K, Brand CL, Cherrington AD 2007 A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog. J Pharmacol Exp Ther 321:743-752 (Pubitemid 46624501)
78. Winzell MS, Brand CL, Wierup N, Sidelmann UG, Sundler F, Nishimura E, Ahrén B 2007 Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. Diabetologia 50:1453-1462 (Pubitemid 46879005)
79. Petersen KF, Sullivan JT 2001 Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44:2018-2024 (Pubitemid 33124047)
80. Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, Reed C, She P, Jetton TL, Demarest KT 2004 Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53:410-417 (Pubitemid 38174557)
81. Sloop KW, Cao JX, Siesky AM, Zhang HY, Bodenmiller DM, Cox AL, Jacobs SJ, Moyers JS, Owens RA, Showalter AD, Brenner MB, Raap A, Gromada J, Berridge BR, Monteith DK, Porksen N, McKay RA, Monia BP, Bhanot S, Watts LM, Michael MD 2004 Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 113:1571-1581 (Pubitemid 39071680)
82. Morgan ES, Brandt TA, Van Dongen MGJ, Geerts BF, Burggraaf J, Romijn JA, Cohen AF, Watanabe TA, Geary RS, Bhanot S 2010 First proof of pharmacology of a novel glucagon receptor antisense drug in humans. Diabetes 59:79 (Abstract)
83. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD 2002 Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 290:839-843 (Pubitemid 34687519)
84. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, Obici S, Tang B, Holst JJ, Fledelius C, Johansen PB, Rossetti L, Jelicks LA, Serup P, Nishimura E, Charron MJ 2003 Lower blood glucose, hyperglucagonemia, and pancreatic α-cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 100: 1438-1443 (Pubitemid 36184020)
85. Hancock AS, Du A, Liu J, Miller M, May CL 2010 Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice. Mol Endocrinol 24:1605-1614
86. Marroquí L, Vieira E, Gonzalez A, Nadal A, Quesada I 2011 Leptin downregulates expression of the gene encoding glucagon in alphaTC1-9 cells and mouse islets. Diabetologia 54:843-851
87. Wang MY, Chen L, Clark GO, Lee Y, Stevens RD, Ilkayeva OR, Wenner BR, Bain JR, Charron MJ, Newgard CB, Unger RH 2010 Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci USA 107:4813-4819
88. Mittendorfer B, Horowitz JF, DePaoli AM, McCamish MA, Patterson BW, Klein S 2011 Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes. Diabetes 60:1474-1477
89. Moon HS, Matarese G, Brennan AM, Chamberland JP, Liu X, Fiorenza CG, Mylvaganam GH, Abanni L, Carbone F, Williams CJ, De Paoli AM, Schneider BE, Mantzoros CS 2011 Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes 60: 1647-1656
90. Hukshorn CJ, van Dielen FM, Buurman WA, Westerterp-Plantenga MS, Campfield LA, Saris WH 2002 The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects. Int J Obes Relat Metab Disord 26:504-509 (Pubitemid 34407263)
91. Zelissen PM, Stenlof K, Lean ME, Fogteloo J, Keulen ET, Wilding J, Finer N, Rössner S, Lawrence E, Fletcher C, McCamish M; Author Group 2005 Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes Metab 7:755-761
92. Yu R, Nissen NN, Dhall D, Heaney AP 2008 Nesidioblastosis and hyperplasia of α-cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas. Pancreas 36:428-431 (Pubitemid 351591587)
93. Zhou C, Dhall D, Nissen NN, Chen CR, Yu R 2009 Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, α-cell hyperplasia, and islet cell tumor. Pancreas 38:941-946
94. Unger RH, Aguilar-Parada E, Müller WA, Eisentraut AM 1970 Studies of pancreatic α-cell function in normal and diabetic subjects. J Clin Invest 49:837-848
95. Raskin P, Unger RH 1978 Effect of insulin therapy on the profiles of plasma immunoreactive glucagon in juvenile-type and adult-type diabetics. Diabetes 27:411-419 (Pubitemid 8324709)
96. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB 1987 Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106-110 (Pubitemid 17015886)
97. Li XC, Liao TD, Zhuo JL 2008 Long-term hyperglucagonaemia induces early metabolic and renal phenotypes of type 2 diabetes in mice. Clin Sci (Lond) 114:591-601 (Pubitemid 351589059)
98. Baron AD, Schaeffer L, Shragg P, Kolterman OG 1987 Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36:274-283 (Pubitemid 18028415)
99. Dimitriadis G, Gerich J 1985 Effect of twice daily subcutaneous administration of a long-acting somatostatin analog on 24-hour plasma glucose profiles in patients with insulin-dependent diabetes mellitus. Horm Metab Res 17:510-511 (Pubitemid 16245518)
100. Grossman LD, Shumak SL, George SR, Singer W, Zinman B 1989 The effects of SMS 201-995 (Sandostatin) on metabolic profiles in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 68: 63-67 (Pubitemid 19028724)
101. Osei K, O'Dorisio TM, Malarkey WB, Craig EL, Cataland S 1989 Metabolic effects of long-acting somatostatin analogue (Sandostatin) in type I diabetic patients on conventional therapy. Diabetes 38:704-709 (Pubitemid 19285722)
102. Orskov L, Møller N, Bak JF, Pørksen N, Schmitz O 1996 Effects of the somatostatin analog, octreotide, on glucose metabolism and insulin sensitivity in insulin-dependent diabetes mellitus. Metabolism 45:211-217 (Pubitemid 26102619)
103. Bruttomesso D, Fongher C, Silvestri B, Barberio S, Marescotti MC, Iori E, Valerio A, Crazzolara D, Pianta A, Tiengo A, Del Prato S 2001 Combination of continuous subcutaneous infusion of insulin and octreotide in type 1 diabetic patients. Diabetes Res Clin Pract 51:97-105 (Pubitemid 32143671)
104. Dinneen S, Alzaid A, Turk D, Rizza R 1995 Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38:337-343
105. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH 1970 Abnormal α-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 283:109-115
106. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, Gerich J 1990 Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 39:1381-1390 (Pubitemid 20372227)
107. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, Gerich J 1992 Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22-29
108. Woerle HJ, Szoke E, Meyer C, Dostou JM, Wittlin SD, Gosmanov NR, Welle SL, Gerich JE 2006 Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 290:E67-E77
109. Ali S, Drucker DJ 2009 Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab 296:E415-E421
110. Engel SS, Xu L, Andryuk PJ, Davies MJ, Amatruda J, Kaufman K, Goldstein BJ 2011 Efficacy and tolerability of MK-0893, a glucagon receptor antagonist, in patients with type 2 diabetes. Diabetes 60:A85 (Abstract)
111. Kelly RP, Garhyan P, Abu-Raddad EJ, Fu H, Lim CN, Prince MJ, Pinaire JA, Loh MT, Deeg MA 2011 Short-term treatment with glucagon receptor antagonist LY2409021 effectively reduces fasting blood glucose and HbA1c in patients with type 2 diabetes mellitus. Diabetes 60:A84 (Abstract)